Bristol-Myers, Vedanta Set Cancer Collaboration

   By Colin Kellaher

Bristol-Myers Squibb Co. (BMY) and Vedanta Biosciences on Monday said they will evaluate Bristol-Myers' cancer drug Opdivo in combination with Vedanta's VE800 microbiome-based immuno-oncology candidate in patients with advanced or metastatic cancers.

Bristol-Myers said it will make an equity investment in Vedanta, an affiliate of Boston biopharmacy company PureTech Health PLC (PRTC.LN), which owned 71.5% of Vedanta as of June 30. Terms of the investment weren't disclosed.

"Our collaboration with Vedanta Biosciences will allow us to gain a deeper understanding about the emerging microbiome landscape, its role in oncology, and the potential to improve outcomes for patients with advanced or metastatic cancer," the New York drug maker said.

The companies said Vedanta will maintain control of its VE800 program, including global research and development and commercial rights.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 10, 2018 08:26 ET (13:26 GMT)

Puretech Health (LSE:PRTC)
Historical Stock Chart
From Mar 2024 to Apr 2024